162 related articles for article (PubMed ID: 17654437)
1. Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
Grant PJ
Diab Vasc Dis Res; 2007 Jun; 4(2):75-6. PubMed ID: 17654437
[No Abstract] [Full Text] [Related]
2. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
Marx N
Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
[No Abstract] [Full Text] [Related]
3. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
4. The rosiglitazone meta-analysis.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
[No Abstract] [Full Text] [Related]
5. The record on rosiglitazone and the risk of myocardial infarction.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
[No Abstract] [Full Text] [Related]
6. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
7. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
McGuire DK
Diab Vasc Dis Res; 2007 Jun; 4(2):77-9. PubMed ID: 17654438
[No Abstract] [Full Text] [Related]
8. Rosiglitazone, marketing, and medical science.
Moynihan R
BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
[No Abstract] [Full Text] [Related]
9. Rosiglitazone and cardiovascular risk.
Mannucci E; Monami M; Marchionni N
N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
[No Abstract] [Full Text] [Related]
10. Rosiglitazone: a thunderstorm from scarce and fragile data.
Mulrow CD; Cornell J; Localio AR
Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398
[No Abstract] [Full Text] [Related]
11. Rosiglitazone and cardiovascular risk.
Diamond GA; Kaul S
N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135
[No Abstract] [Full Text] [Related]
12. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
13. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
14. Rosiglitazone and cardiovascular risk.
Kaul S; Diamond GA
Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
[TBL] [Abstract][Full Text] [Related]
15. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
Erdmann E; Scherbaum WA
MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
[No Abstract] [Full Text] [Related]
16. Is rosiglitazone as safe as BARI 2D and the reanalysis of RECORD imply?
DiNicolantonio JJ; Meier P
Cardiology; 2014; 127(3):152-4. PubMed ID: 24335113
[No Abstract] [Full Text] [Related]
17. In brief: rosiglitazone (Avandia) unbound.
Med Lett Drugs Ther; 2014 Feb; 56(1435):12. PubMed ID: 24662977
[No Abstract] [Full Text] [Related]
18. Faster publication isn't always better.
Fuster V; Farkouh ME
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
[No Abstract] [Full Text] [Related]
19. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
[TBL] [Abstract][Full Text] [Related]
20. The rosigliazone meta-analysis: lessons for the future.
Shuster JJ; Schatz DA
Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
[No Abstract] [Full Text] [Related]
[Next] [New Search]